Novartis Pharma AG: New long-term Rhapsido (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)
Novartis announced 52-week Phase III data for Rhapsido (remibrutinib) in chronic inducible urticaria (CIndU), showing sustained efficacy and a consistent safety profile. The study met primary endpoints, with significant response rates in SD, ColdU, and CholU subtypes. Novartis plans additional regulatory submissions based on these results.
How this was made
The 30-second read
Why it matters
The data could expand Rhapsido's label, increase sales potential, and boost Novartis' immunology franchise.
Market read
First‑report Phase III results are material for Novartis' valuation and may trigger short‑term buying pressure.
What to watch
Potential reimbursement challenges and the need for larger Phase III confirmatory studies could temper upside.
Background
Novartis announced the first long‑term efficacy data from its RemIND Phase III trial of Rhapsido in chronic inducible urticaria, a condition affecting ~0.5% of the population.
Ticker impact
Novartis released 52‑week Phase III data for Rhapsido (remibrutinib) showing sustained efficacy and safety in chronic inducible urticaria.
potential upside as investors price in expanded indication and upcoming regulatory submissions
Data demonstrate strong response rates across subtypes and a favorable safety profile, supporting further approvals and market expansion.
Market effects
Strengthens the broader biotech/immune‑modulating sector as a successful BTK inhibitor may set a precedent for similar therapies.
Positive for European and US pharma markets where Novartis is a major component.
Adds to global pipeline confidence for chronic urticaria treatments.
Counterpoint
If regulatory hurdles delay approval or competition intensifies, the data may be priced out quickly.
Key entities
- companyNovartis Pharma AG
Swiss multinational pharmaceutical company developing Rhapsido.
- drugRhapsido (remibrutinib)
Oral BTK inhibitor targeting chronic inducible urticaria.




